Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Neuroscience Right
  3. Emgality (galcanezumab-gnlm) injection Right
  4. Is it necessary to stop Emgality® (galcanezumab-gnlm) before becoming pregnant?
Search Emgality (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Emgality ® (galcanezumab-gnlm) injection

100 mg/mL, 120 mg/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Is it necessary to stop Emgality® (galcanezumab-gnlm) before becoming pregnant?

There is no information on which to base a recommendation for a washout period for those who are receiving Emgality (galcanezumab) and are planning to become pregnant.

US_cFAQ_GLC203_X3_PREGNANCY_WASHOUT
US_cFAQ_GLC203_X3_PREGNANCY_WASHOUT
en-US

Planning to Become Pregnant

No Adverse Effect Observed on Fertility Parameters With Galcanezumab Exposure (Preclinical Data Only)

There are no adequate data on the effect on fertility with the use of galcanezumab in humans, as patients of reproductive potential were required to use birth control during the studies.1

Galcanezumab was administered to rats at subcutaneous doses of up to 250 mg/kg  (representing exposures 4-18 times the highest proposed clinical dose of 300 mg).2 No adverse effect was observed on fertility parameters such as

  • reproductive organs
  • estrous cycle
  • sperm analysis, or
  • mating and fertility.1,2

No Adverse Effect Observed on Fetal Development or Postnatal Parameters with Galcanezumab Exposure (Preclinical Data Only)

Embryofetal development studies conducted in rats and rabbits at exposures greater than expected clinically revealed no evidence of harm to the developing fetus.2

In offspring exposed to galcanezumab in utero and through lactation at exposures greater than expected clinically in the prenatal and postnatal development study in rats, there were no effects on

  • survival
  • growth
  • sexual maturation
  • behavior, or
  • reproduction.1,2

No Information for Recommendation of Galcanezumab Washout Period Prior to Pregnancy

There is no information on which to base a recommendation for a washout period for those who are receiving galcanezumab and are planning to become pregnant.

Galcanezumab is an IgG4 monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.2,3

The elimination half-life (t1/2) of galcanezumab is 27 days.2,3

HCP Considerations When Prescribing Galcanezumab to a Patient Who is Planning to Become Pregnant

In determining the most appropriate approach in a patient treated with galcanezumab who is planning to become pregnant, clinicians should

  • take into consideration the t1/2 of the molecule, and
  • use their clinical judgment.

Pregnancy Registry and Observational Study Will Compare Maternal, Fetal, and Infant Outcomes

A pregnancy exposure registry and subsequent registry-based prospective observational study in the United States will compare maternal, fetal, and infant outcomes.

This study will enroll mothers with live births into each of the following groups:

  • women with migraine exposed to galcanezumab up to 5 months before or during pregnancy
  • pregnant women with migraine exposed to other migraine preventative medications, and
  • pregnant women with migraine not exposed to migraine preventative medications.4

Lilly Migraine Pregnancy Registry Enrollment Information

Eligible women may self-enroll, or be enrolled by their healthcare provider into the Lilly Migraine Pregnancy Registry by

  • accessing the registry website at www.migrainepregnancyregistry.com, or
  • calling 1-833-464-4724.2,4

This registry is only available in the United States.

Enclosed Prescribing Information

EMGALITY® (galcanezumab-gnlm) injection, for subcutaneous use, Lilly

References

The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).

1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

3Kielbasa W, Helton DL. A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780

4Ephross SA, Schroeder KM, Kellier-Steele NA, et al. Registry-based, prospective, observational study to assess maternal, fetal, and infant outcomes following exposure to migraine treatments, including galcanezumab. Poster presented at: Diamond Headache Clinic Research & Educational Foundation; July 15-18, 2021; Lake Buena Vista, FL.

Date of Last Review: June 25, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly